Tizona Therapeutics Obtains $43,000,000 Series B Funding

  • Feed Type
  • Date
    3/8/2016
  • Company Name
    Tizona Therapeutics
  • Mailing Address
    601 Gateway Blvd. South San Francisco, CA 94080 USA
  • Company Description
    Tizona Therapeutics, Inc. is a preclinical stage biotechnology company that is developing multiple, innovative immuno-oncology therapies.
  • Website
    http://www.tizonatx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $43,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Proceeds will be used to advance the company’s immunotherapy programs. We expect Tizona’s anti-CCR4 antibody to play an important role in inducing antitumor activity by depleting regulatory T cells (Tregs), a type of cell crucial to establishing and maintaining an immunosuppressive tumor microenvironment. In addition to the anti-CCR4 antibody program, proceeds from the financing will be used to advance Tizona’s pipeline, including the company’s IL-35 programs. IL-35 is a recently discovered immunosuppressive cytokine, predominantly expressed by Tregs.
  • M&A Terms
  • Venture Investor
    Abingworth
  • Venture Investor
    Canaan Partners
  • Venture Investor
    Lightstone Ventures
  • Venture Investor
    MPM Capital
  • Venture Investor
    Amgen Ventures
  • Venture Investor
    Astellas Venture Capital
  • Venture Investor
    InterWest Partners